Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age, 18 to 85 years inclusive~* Brain MRI findings consistent with early stroke onset~* Clinical diagnosis of acute ischemic stroke with disabling neurological deficit~* Stroke symptoms present for at least 30 minutes with no significant improvement before treatment~* Be last known well (without stroke symptoms) within 24 hours of triage~* Be able to receive IV rt-PA within 4.5 hours from the time the symptoms were discovered.~* MRI diagnostic of acute ischemic stroke and consistent with clinical syndrome~* Time between completion of qualifying MRI studies to treatment initiation ≤ 1 hour~Exclusion Criteria:~* History of intracranial hemorrhage~* Symptoms rapidly improving or only minor before start of study drug.~* Severe stroke as assessed clinically (e.g., NIHSS score \>25) or by appropriate imaging techniques (lesion volume \> one-third of MCA by visual inspection or \>100 cm3 using the ellipsoid estimation formula of ABC/2)~* Stroke or serious head trauma within the previous 3 months~* Administration of heparin within the 48 hours preceding the onset of stroke, with an activated partial-thromboplastin time at presentation exceeding the upper limit of the normal range~* Platelet count of less than 100,000 per cubic millimeter~* Uncontrolled hypertension defined as systolic blood pressure \> 185 mm Hg or diastolic blood pressure \> 110 mm Hg that cannot be controlled except with continuous parenteral antihypertensive medication~* Blood glucose less than 50 mg per deciliter or greater than 400 mg per deciliter~* Symptoms suggestive of subarachnoid hemorrhage, even if CT/MRI scan was normal~* Oral anticoagulant treatment, regardless of INR.~* Major surgery or severe trauma within the previous 3 months~* Other major disorders associated with an increased risk of bleeding~* Eligible for rt-PA therapy per institutional protocol as part of routine clinical practice~* Non-ischemic etiology demonstrated by neuroimaging~* Neuroimaging (CT or gradient echo MRI) evidence of acute or chronic ICH (non-microbleed)~* Presence of 10 or more microbleeds on GRE (suggestive of amyloid angiopathy)~* Any contraindication for MRI, e.g. presence of a pacemaker, ferromagnetic aneurysm clip, etc, pre-menopausal women with a positive pregnancy blood test, or severe claustrophobia.~* Poor quality MRI- images are not interpretable~* In the opinion of the investigator, the patient is not an appropriate candidate for IV rt-PA~* Women known to be pregnant, lactating or having a positive or indeterminate pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- IV rt-PA (Type: EXPERIMENTAL): open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).